SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-150883
Filing Date
2022-05-16
Accepted
2022-05-16 07:26:10
Documents
14
Period of Report
2022-05-10
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d361453d8k.htm   iXBRL 8-K 35184
2 EX-10.1 d361453dex101.htm EX-10.1 72091
3 EX-10.2 d361453dex102.htm EX-10.2 64627
  Complete submission text file 0001193125-22-150883.txt   339898

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA zntl-20220510.xsd EX-101.SCH 2860
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE zntl-20220510_lab.xml EX-101.LAB 17995
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE zntl-20220510_pre.xml EX-101.PRE 11264
8 EXTRACTED XBRL INSTANCE DOCUMENT d361453d8k_htm.xml XML 3354
Mailing Address 1359 BROADWAY, SUITE 1710 NEW YORK NY 10018
Business Address 1359 BROADWAY, SUITE 1710 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Filer) CIK: 0001725160 (see all company filings)

IRS No.: 823607803 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39263 | Film No.: 22925452
SIC: 2834 Pharmaceutical Preparations